Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 3
2015 1
2016 1
2017 2
2018 1
2019 1
2020 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
▾Indacaterol for COPD.
[No authors listed] [No authors listed] Drug Ther Bull. 2012 May;50(5):58-60. doi: 10.1136/dtb.2012.05.0105. Drug Ther Bull. 2012. PMID: 22573707
Indacaterol powder for inhalation (Onbrez Breezhaler - Novartis) is a long-acting beta(2) agonist, licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). ...
Indacaterol powder for inhalation (Onbrez Breezhaler - Novartis) is a long-acting beta(2) agonist, licensed for once-daily use …
Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler() 150 and 300 mug.
Abadelah M, Chrystyn H, Bagherisadeghi G, Abdalla G, Larhrib H. Abadelah M, et al. AAPS PharmSciTech. 2018 Jan;19(1):251-261. doi: 10.1208/s12249-017-0841-y. Epub 2017 Jul 10. AAPS PharmSciTech. 2018. PMID: 28695328
Onbrez Breezhaler is a low-resistance capsule-based device that was developed to deliver indacaterol maleate. ...These in vitro results suggest that a minimum MIF of 60 L/min is required during routine use of Onbrez Breezhaler, and confirm the good pra …
Onbrez Breezhaler is a low-resistance capsule-based device that was developed to deliver indacaterol maleate. ...These in vitr …
Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.
McKeage K. McKeage K. Drugs. 2012 Mar 5;72(4):543-63. doi: 10.2165/11208490-000000000-00000. Drugs. 2012. PMID: 22356291 Review.
Indacaterol inhalation powder (Onbrez Breezhaler) is a long-acting, selective beta(2)-adrenoceptor agonist that is indicated for the maintenance bronchodilator treatment of airflow obstruction in adults with chronic obstructive pulmonary disease (COPD). ...
Indacaterol inhalation powder (Onbrez Breezhaler) is a long-acting, selective beta(2)-adrenoceptor agonist that is indicated f …
Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
Horváth A, Farkas Á, Szipőcs A, Tomisa G, Szalai Z, Gálffy G. Horváth A, et al. Eur J Pharm Sci. 2020 Nov 1;154:105508. doi: 10.1016/j.ejps.2020.105508. Epub 2020 Aug 21. Eur J Pharm Sci. 2020. PMID: 32836137 Free article.
Patient specific emitted doses and particle size distributions were determined for Symbicort Turbuhaler, Onbrez Breezhaler, Seebri Breezhaler and Bretaris Genuair aerosol drugs. ...
Patient specific emitted doses and particle size distributions were determined for Symbicort Turbuhaler, Onbrez Breezhaler, Se …
Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers.
Tavernini S, Farina DJ, Martin AR, Finlay WH. Tavernini S, et al. Pharm Res. 2021 Sep;38(9):1601-1613. doi: 10.1007/s11095-021-03082-0. Epub 2021 Aug 31. Pharm Res. 2021. PMID: 34463937
Regional deposition (tracheobronchial and alveolar) for four DPIs (Onbrez Breezhaler, Flovent Diskus, Pulmicort Turbuhaler, and Asmanex Twisthaler) was estimated using cascade impactor measurements and an in silico regional deposition model. ...
Regional deposition (tracheobronchial and alveolar) for four DPIs (Onbrez Breezhaler, Flovent Diskus, Pulmicort Turbuhaler, an …
Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
Shimada S, Vaidya S, Khindri S, Tashiro N, Cheng Y, Hara H, Majumdar T, Woessner R, Furihata K, Kobayashi K. Shimada S, et al. Int J Clin Pharmacol Ther. 2015 May;53(5):398-407. doi: 10.5414/CP202239. Int J Clin Pharmacol Ther. 2015. PMID: 25740265 Clinical Trial.
OBJECTIVES: This study aimed to evaluate influence of ethnic factors on the pharmacokinetics of orally inhaled QMF149, a novel combination of an approved longacting beta2-agonist, indacaterol (Onbrez Breezhaler for COPD), and an approved inhaled corticosteroid, mome …
OBJECTIVES: This study aimed to evaluate influence of ethnic factors on the pharmacokinetics of orally inhaled QMF149, a novel combination o …
Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea.
Yum HK, Kim HR, Chang YS, Shin KC, Kim S, Oh YM. Yum HK, et al. Tuberc Respir Dis (Seoul). 2017 Jan;80(1):52-59. doi: 10.4046/trd.2017.80.1.52. Epub 2016 Dec 30. Tuberc Respir Dis (Seoul). 2017. PMID: 28119747 Free PMC article.
BACKGROUND: Inhaled indacaterol (Onbrez Breezhaler), a long-acting beta(2)-agonist, is approved in over 100 countries, including South Korea, as a once-daily bronchodilator for maintenance and treatment of chronic obstructive pulmonary disease (COPD). ...
BACKGROUND: Inhaled indacaterol (Onbrez Breezhaler), a long-acting beta(2)-agonist, is approved in over 100 countries, includi …
11 results